Navigation Links
Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting
Date:11/6/2009

l results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.

SOURCE Oncolytics Biotech Inc.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... May 22, 2015 Knowledgent , ... paper that explores the potential of big data analytics ... paper was developed to help life sciences and healthcare ... data to gain critical business insights. , The life ... of data driven by patient profiling, compliance and regulatory ...
(Date:5/22/2015)... Baylor Research Institute (BRI) at Dallas ... in Phoenix, AZ , today announce an ... for patients with a broad range of cancers. Aligning the ... trials and access to technology to drive the development of ... across Baylor Scott & White Health,s 49 hospitals ...
(Date:5/21/2015)... 21, 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or ... that develops and commercializes proprietary technologies and products for ... results for the second fiscal quarter ended March 31, ... continued to advance business with our existing customers and ... President and CEO of SQI. "The delivery of a ...
(Date:5/21/2015)... MO (PRWEB) May 21, 2015 Seventh ... the safety and efficacy of pharmaceutical products and medical ... Maryland Heights, MO 63043, a 50,000 sq. ft. building ... location, to enable strategic growth. Facility renovations will begin ... the new space will occur in September. , ...
Breaking Biology Technology:New White Paper Explores the Potential of Big Data Analytics in Life Sciences and Healthcare 2Precision Medicine Collaboration to Increase Options for Cancer Patients 2Precision Medicine Collaboration to Increase Options for Cancer Patients 3Precision Medicine Collaboration to Increase Options for Cancer Patients 4SQI Diagnostics Reports Second Quarter Financial Results 2SQI Diagnostics Reports Second Quarter Financial Results 3SQI Diagnostics Reports Second Quarter Financial Results 4SQI Diagnostics Reports Second Quarter Financial Results 5SQI Diagnostics Reports Second Quarter Financial Results 6SQI Diagnostics Reports Second Quarter Financial Results 7SQI Diagnostics Reports Second Quarter Financial Results 8Seventh Wave Laboratories Purchases Building for Expansion, Upcoming Move 2Seventh Wave Laboratories Purchases Building for Expansion, Upcoming Move 3
... Trial with James Pingpank, MD, FACS, as Principal Investigator , ... Delcath Systems, Inc. (Nasdaq: DCTH ) ... University of Pittsburgh Medical Center (UPMC), has joined ... (PHP) System against inoperable metastatic melanoma in the liver. ...
... CARMEL, Israel, December 2 InSightec Ltd. announced,today ... (MRgFUS) with the ExAblate(R) system has the potential ... that have spread to,the bones (bone metastases). The ... the,November 11 online issue of Annals of Surgical ...
... Calif., Dec. 2 Intradigm Corporation, a leading,developer ... the issuance of United States patent 7,459,547, entitled ... The issued,patent, which is based on the ... Cook Chair of Biomedical Sciences and Professor of ...
Cached Biology Technology:Delcath Adds University of Pittsburgh Medical Center to Phase III Trial 2Delcath Adds University of Pittsburgh Medical Center to Phase III Trial 3Delcath Adds University of Pittsburgh Medical Center to Phase III Trial 4New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases 2New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases 3New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases 4Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics 2Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics 3
(Date:4/8/2015)... CHARLOTTE, N.C. , April 8, 2015 /PRNewswire/ ... technology solutions and services, and Morpho, a leading ... in partnership to produce the market,s most advanced ... Infinisource,s iSolved NXG time clock is setting ... attendance and labor data for the small and ...
(Date:4/2/2015)... 2015 In the current ... outperforms the strongest competitors, showing outstanding performance in ... system is capable of a throughput of 5.000.000 ... to be ten times faster than most competitors ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) ...
(Date:4/2/2015)... -- According to preliminary estimates Fingerprint Cards, ... than 125 MSEK. This exceeds the guidance provided by ... for Q1 2015 would be in line with the ... The operating result for the first quarter is estimated ... will as previously communicated be published on May 21. ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Revises Revenues for Q1 2015 2
... Hill, N.C. -- Researchers at Duke University Medical Center and ... a single disrupted gene can cause a form of severe ... a study published in the journal Nature Neuroscience , ... neurons in the brain can form and adjust their ...
... Huntsville, Ala. Dr. Casey Weaver, University of Alabama ... 2009 HudsonAlpha Prize for Outstanding Innovation in Life Sciences. ... salutes Weaver,s achievements in advancing understanding of immune protection ... According to Weaver, our bodies use T cells to ...
... HOUSTON (May 7, 2009) Dr. Gail Demmler-Harrison ... (SPR) 2009 Thomas Hazinski, M.D. Distinguished Service Award. ... Hospital and professor of Pediatrics at Baylor College of ... Societies, Annual Meeting in Baltimore, MD. The ...
Cached Biology News:Preclinical work shows how one gene causes severe mental retardation 2Preclinical work shows how one gene causes severe mental retardation 3UAB professor receives HudsonAlpha Innovation Prize 2
DTT, 25g...
...
...
Antibody specific for trimethyl-Lys27 of histone H3. Mouse monoclonal. Antigen: Synthetic peptide derived from histone H3, trimethylated at lysine 27...
Biology Products: